Agios Pharmaceuticals announced the initiation of a Phase 1/2 multicenter study of AG-221 in patients with advanced solid tumors. Pluristem Therapeutics announced it has completed development of its second major product line.

U.S. stock indexes are following other global markets lower in early trading. European stocks fell after Germany reported the biggest monthly drop in industrial production in five years.